Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
500 participants
OBSERVATIONAL
2019-06-06
2019-09-17
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
However, it is not known if the presence (or absence) of these atypical features by themselves are indeed signs of non-diabetic renal disease and necessitate to perform renal biopsy. The aim of the study is to determine if these atypical features are relevant indications to perform renal biopsy. To answer this question, will be analyze the medical records of patients with type 2 diabetes who underwent renal biopsy in five French nephrology center to determine, in each case, the indication of the biopsy and if this latter benefitted the patients.
In addition, will be evaluate the prognosis value of the Renal Pathology Society classification of diabetic nephropathy in patients with type 2 diabetes and diabetic nephropathy.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Molecular Analysis of Diabetic Kidney Disease Biopsies
NCT04029402
A Phase 1, Open-label Safety Study of NKA in Patients With Type 2 Diabetes
NCT02008851
Prediabetes in End Stage Renal Disease on Dialysis
NCT07337083
An Observational, Cross Sectional Study to Assess the Prevalence of Chronic Kidney Disease (CKD) in Type 2 Diabetes Patients
NCT02208921
A Study to Learn More About Chronic Kidney Disease (CKD) in Patients With Type 2 Diabetes Mellitus (T2DM)
NCT05004428
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Will be collected demographical, clinical and biological data at the time of the renal biopsy and at the last follow-up from the patients' medical charts.
Indications for renal biopsy will be categorized as
1. Atypical feature of etiological significance in the presence of any atypical feature not listed below (including acute kidney injury as defined by the stage 1 of KDIG guidelines)
2. Brutal nephrotic syndrome in the absence of the above criterion
3. Rapid decline of GFR (defined as 50 % eGFR decline over \>1 week but \< 1 year) in the absence of criteria 1-2
4. Absence of proteinuria in the absence of criteria 1-3
5. Rapid increase of proteinuria in the absence of criteria 1-4
6. Presence of hematuria in the absence of criteria 1-5
7. Absence of diabetic retinopathy in the absence of criteria 1-6 Will be evaluate the actual probability to reach a non-diabetic renal disease for each of these indications.
Will be also perform a classical analysis by assessing the association of clinical and biological feature such as HbA1c, diabetes duration, absence of diabetic retinopathy,… with the presence of a non-diabetic renal disease.
In addition, the biopsy samples will be scored according to the RPS diabetic nephropathy classification to evaluate the prognostic value of this classification.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Over 18 year old
* With a first non-transplant renal biopsy for non-tumoral indication between 01/01/2006 and 12/31/2015
Exclusion Criteria
* Patients with previous renal biopsy
* Patients with non-type 2 diabetes (type 1, post-pancreatitis, genetic, etc.)
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Rennes University Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jonathan Chemouny
Role: PRINCIPAL_INVESTIGATOR
Rennes University Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
AP-HM, Hôpital de la Conception
Marseille, , France
AP-HP, Hôpital Bichat-Claude Bernard
Paris, , France
Rennes University Hospital
Rennes, , France
Hôpital Bretonneau
Tours, , France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
35RC19_30031_RIB-R2D2
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.